Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Settlement Over Vanlev Could Require Clinical Trial Disclosure

This article was originally published in The Pink Sheet Daily

Executive Summary

Proposed settlement would resolve class action suit alleging Bristol misled investors about safety problems with its failed investigational antihypertensive.

You may also be interested in...



GSK Settles With N.Y.; Company Will Post Past Trial Data By End Of 2005

The settlement includes a modest $2.5 mil. disgorgement fee. GSK is also required to advertise the clinical trial register in seven prominent peer reviewed journals.

Biden Launches Effort To Strengthen US Pharmaceutical Supply Chain

A fresh executive order from US president Joe Biden calls for short-term and long-term study, broad consultation, and co-ordination with allies on the domestic supply chain.

Biden Launches Effort To Strengthen US Pharmaceutical Supply Chain

Executive order calls for short-term and long-term study, broad consultation, coordination with allies.

Topics

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel